Stockscreener 앱 받기
1.78
1.14%
0.02
시간 외 거래:
1.76
-0.02
-1.12%
Aldeyra Therapeutics Inc 주식(ALDX)의 최신 뉴스
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Connect - ACCESS Newswire
Aldeyra appoints Darlene Deptula-Hicks to board of directors By Investing.com - Investing.com Nigeria
Aldeyra Therapeutics (ALDX) grants director options on 73,318 shares - Stock Titan
Aldeyra Therapeutics (ALDX) director receives three new stock option grants - Stock Titan
Aldeyra Therapeutics (ALDX) director receives new stock option awards - Stock Titan
Aldeyra Therapeutics (ALDX) grants board member new stock option awards - Stock Titan
[Form 4] Aldeyra Therapeutics, Inc. Insider Trading Activity - Stock Titan
Aldeyra (ALDX) director granted multiple new stock option awards - Stock Titan
Aldeyra Therapeutics (ALDX) director receives long-dated stock option awards - Stock Titan
Aldeyra Therapeutics (ALDX) director Deptula-Hicks submits initial Form 3 - Stock Titan
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Aldeyra Therapeutics Adds Independent Director, Affirms Governance Support - The Globe and Mail
Aldeyra Therapeutics CEO, President & Director Acquires 18% More Stock - simplywall.st
CEO, President & Director of Aldeyra Therapeutics Picks Up 18% More Stock - Yahoo Finance
Darlene Deptula-Hicks joins Aldeyra (ALDX) board as audit committee chair - Stock Titan
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors - BioSpace
What Does Darlene Deptula-Hicks Bring to Aldeyra's Board - Kavout
Aldeyra appoints Darlene Deptula-Hicks to board of directors - Investing.com
Aldeyra Therapeutics eyes FDA feedback as dry eye drug faces make-or-break moment - MSN
Why Did ALDX Stock Tank 70% Today? - Stocktwits
Todd Brady Increases Stake in Aldeyra Therapeutics Inc with Sign - GuruFocus
Todd Brady Increases Stake in Aldeyra Therapeutics Inc with Significant Share Purchase - GuruFocus
Aldeyra Therapeutics CEO Todd Brady buys $418,450 in stock By Investing.com - Investing.com Australia
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Aldeyra Therapeutics CEO Todd Brady buys $418,450 in stock - Investing.com
Aldeyra Therapeutics Insider Bought Shares Worth $418,450, According to a Recent SEC Filing - marketscreener.com
Aldeyra (NASDAQ: ALDX) CEO Todd Brady purchases 250,000 common shares - Stock Titan
3 Promising Penny Stocks With Market Caps Reaching $300M - Sahm
Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment - inkl
ALDX: Late-stage dry eye program nears key FDA decision, with strong cash and AbbVie partnership - TradingView
Aldeyra Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline AdvancesCore Business Growth - newsline.com
Aldeyra Therapeutics CEO to Speak at Jefferies Global Healthcare Conference - GuruFocus
Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - Business Wire
ALDX Technical Analysis | Trend, Signals & Chart Patterns | ALDEYRA THERAPEUTICS INC (NASDAQ:ALDX) - ChartMill
ALDX Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Pipeline ProgressEPS Surprise History - newsline.com
Lawsuit filed for Investors who lost money with shares of Zoetis Inc. (NYSE: ZTS) - openPR.com
ANGI Investors Have Opportunity to Join Angi Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Investor Alert: Deadline in Lawsuit on May 29, 2026 - openPR.com
Gossamer Bio, Inc. (NASDAQ: GOSS) Investor Alert: Deadline in Lawsuit on June 1, 2026 - openPR.com
Aldeyra Therapeutics Faces Class Action Deadline Amid FDA Rejections (ALDX) - GuruFocus
ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra - GuruFocus
ALDX DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts Aldeyra Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit Today - ACCESS Newswire
Aldeyra Therapeutics Faces Securities Fraud Lawsuit Amid FDA Rej - GuruFocus
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - 巴士的報
ALDX UPCOMING DEADLINE : The Gross Law Firm Alerts Aldeyra - GlobeNewswire
1.27%
1.43%
자본화:
|
볼륨(24시간):